Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Bendamustine prolongs progression-free survival in metastatic breast cancer
November 10th, 2005
Researchers claim that bendamustine prolongs progression-free survival in metastatic breast cancer (MBC). "Two i.v. regimens, bendamustine, methotrexate and 5-fluorouracil (BMF) and cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were compared as first-line therapy in a randomized, open, multicenter phase III trial including 364 patients with MBC. Bendamustine is an anti-neoplastic agent with alkylating, but also additional, so far unclear, mechanisms of action," scientists writing in the journal Anti-Cancer Drugs reported. "We wanted to show the superiority of BMF over CMF in terms of time to progression (TTP) (primary endpoint),...
Source: Women's Health Weekly (2005-11-10)
|
